AstraZeneca reports Mixed Phase III Results for Ultomiris in Rare Post-Transplant Blood Disorder
AstraZeneca's Alexion unit has reported divergent outcomes from its late-stage program testing Ultomiris (ravulizumab) in patients with thrombotic microangiopathy following hematopoietic stem cell transplant (HSCT-TMA), a rare and...
Zydus Collaborates with ICMR to Address Sickle Cell Disease as Desidustat Enters Phase III
Zydus Lifesciences Limited, in collaboration with the Indian Council of Medical Research (ICMR), has announced the successful completion of Phase II Proof-of-Concept trials and approval...
Emcure Pharma Receives CDSCO Approval to Launch Poviztra®️ for Fatty Liver Disease Treatment
Emcure Pharmaceuticals Ltd announced that its co-marketed semaglutide brand, Poviztra®, has received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) for the...
DCGI Approves Qdenga, Marking India’s First Dengue Vaccine
Takeda Biopharmaceuticals India has received market authorisation from the Drug Controller General of India (DCGI) for Qdenga, making it the country's first licensed dengue vaccine....
NATCO Gets USFDA Nod for Generic Cancer Drug Olaparib
Alembic Pharmaceuticals Limited announced that its development partner, NATCO Pharma Limited (NATCO), has received tentative approval from the U.S. Food and Drug Administration (USFDA)...
AstraZeneca Licenses Novel Lung Cancer Drug Zegfrovy in $1.5B Global Deal
AstraZeneca announced a exclusive global license agreement with Dizal Pharmaceutical to develop and commercialize Zegfrovy (sunvozertinib), a highly differentiated, oral irreversible EGFR inhibitor designed for targeted lung cancer...
